{"id":"W2594478488","doi":"10.1158/1538-7445.sabcs16-pd2-07","title":"Abstract PD2-07: 10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Exemestane; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Tamoxifen; Clinical endpoint; Adjuvant therapy; Cancer; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009900681,0.0001776688,0.0004042621,0.0001018146,0.0004719814,0.00009682329,0.0004771955,0.00007667332,0.0001627201],"category_scores_gemma":[0.001020503,0.0001082562,0.000170289,0.0001135878,0.0008705384,0.0002731291,0.0002099889,0.0003234793,0.000006584385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001669747,"about_ca_system_score_gemma":0.0005519549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009086582,"about_ca_topic_score_gemma":0.0001778998,"domain_scores_codex":[0.9979016,0.00007414542,0.000346482,0.000445439,0.0006996386,0.0005327571],"domain_scores_gemma":[0.9976388,0.0003781195,0.000224542,0.001209341,0.0004201714,0.0001290731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.5339779,0.0002696653,0.002572629,0.000307626,0.0004894239,0.00001085692,0.0005733037,0.000002500672,0.2390546,0.000229317,0.0167409,0.2057713],"study_design_scores_gemma":[0.3049022,0.001921624,0.1543123,0.0009572227,0.00007057471,0.00001685673,0.0005916214,0.00001855268,0.1825375,0.001623674,0.352694,0.0003538402],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834711,0.003226586,0.00001561976,0.006585219,0.0007242721,0.002633764,0.000449476,0.00001985113,0.002874101],"genre_scores_gemma":[0.9832999,0.0011471,0.00008364352,0.00007100961,0.0007063914,0.0004883784,0.00001165473,0.00004903417,0.01414287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3359531,"threshold_uncertainty_score":0.441456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.144528455159949,"score_gpt":0.452491500223539,"score_spread":0.30796304506359,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}